| scholarly article | Q13442814 |
| editorial | Q871232 |
| P50 | author | John M. Luk | Q42935545 |
| P2093 | author name string | Nikki P Lee | |
| Guo-Hao Wu | |||
| Zhi-Jie Li | |||
| Ester Khin | |||
| Dong-Xing Cao | |||
| Xiao-Ou Jiang | |||
| Yick Liang Lum | |||
| P2860 | cites work | Transcription factor Late SV40 Factor (LSF) functions as an oncogene in hepatocellular carcinoma | Q24631107 |
| Ets-1 and runx2 regulate transcription of a metastatic gene, osteopontin, in murine colorectal cancer cells | Q28237966 | ||
| cDNA cloning, mRNA distribution and heterogeneity, chromosomal location, and RFLP analysis of human osteopontin (OPN) | Q28258326 | ||
| Osteopontin: role in cell signaling and cancer progression | Q28291041 | ||
| Genomic aberrations in hepatocellular carcinoma related to osteopontin expression detected by array-CGH. | Q33510952 | ||
| An in vivo platform for tumor biomarker assessment | Q34064633 | ||
| The metastasis gene osteopontin: a candidate target for cancer therapy | Q34515780 | ||
| Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer | Q34655823 | ||
| Pharmacokinetic characterization of an RNA aptamer against osteopontin and demonstration of in vivo efficacy in reversing growth of human breast cancer cells | Q35142045 | ||
| Butyrate suppresses mRNA increase of osteopontin and cyclooxygenase-2 in human colon tumor tissue | Q35857523 | ||
| Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. | Q35953813 | ||
| Structural and functional studies of the early T lymphocyte activation 1 (Eta-1) gene. Definition of a novel T cell-dependent response associated with genetic resistance to bacterial infection | Q36356561 | ||
| DNAJB6 chaperones PP2A mediated dephosphorylation of GSK3β to downregulate β-catenin transcription target, osteopontin | Q37029660 | ||
| Role of osteopontin in cellular signaling and metastatic phenotype | Q37175283 | ||
| Osteopontin as a target for cancer therapy | Q37175298 | ||
| Identification of osteopontin as a novel marker for early hepatocellular carcinoma | Q37557988 | ||
| Osteopontin: an effector and an effect of tumor metastasis. | Q37703338 | ||
| Role of the metastasis-promoting protein osteopontin in the tumour microenvironment | Q37769582 | ||
| The cancer biomarker osteopontin: combination with other markers. | Q37956610 | ||
| A small interfering RNA targeting osteopontin as gastric cancer therapeutics | Q38288385 | ||
| Sp1 regulates osteopontin expression in SW480 human colon adenocarcinoma cells | Q38299325 | ||
| Micro-RNA-181a regulates osteopontin-dependent metastatic function in hepatocellular cancer cell lines | Q38343017 | ||
| Cyclooxygenase-2 inhibitors down-regulate osteopontin and Nr4A2-new therapeutic targets for colorectal cancers | Q38352916 | ||
| Nitric oxide-dependent osteopontin expression induces metastatic behavior in HepG2 cells | Q38441703 | ||
| Elevated expression of secreted phosphoprotein I (osteopontin, 2ar) as a consequence of neoplastic transformation. | Q38728996 | ||
| Clinical significance of plasma osteopontin level in Egyptian patients with hepatitis C virus-related hepatocellular carcinoma | Q38986856 | ||
| Suppression of tumor growth in xenograft model mice by small interfering RNA targeting osteopontin delivery using biocompatible poly(amino ester). | Q39359257 | ||
| The potential of osteopontin as a therapeutic target for human colorectal cancer | Q39592866 | ||
| Lentiviral-mediated siRNA targeted against osteopontin suppresses the growth and metastasis of gastric cancer cells | Q39599283 | ||
| Overexpression of osteopontin in hepatocellular carcinoma and its relationships with metastasis, invasion of tumor cells | Q39614988 | ||
| Down-regulation of osteopontin inhibits metastasis of hepatocellular carcinoma cells via a mechanism involving MMP-2 and uPA. | Q39617638 | ||
| Osteopontin promotes hepatocellular carcinoma invasion by up-regulating MMP-2 and uPA expression | Q39628244 | ||
| Thrombin is a therapeutic target for metastatic osteopontin-positive hepatocellular carcinoma | Q39648432 | ||
| Regulation of osteopontin and related proteins in rat CC531 colorectal cancer cells. | Q39685809 | ||
| Expression and prognostic significance of osteopontin and caspase-3 in hepatocellular carcinoma patients after curative resection | Q39722337 | ||
| Osteopontin splice variants differentially modulate the migratory activity of hepatocellular carcinoma cell lines | Q39780008 | ||
| Specific expression of osteopontin and S100A6 in hepatocellular carcinoma | Q39784164 | ||
| A humanized anti-osteopontin antibody inhibits breast cancer growth and metastasis in vivo | Q39810957 | ||
| EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells | Q39913445 | ||
| Lentiviral-mediated miRNA against osteopontin suppresses tumor growth and metastasis of human hepatocellular carcinoma | Q39923530 | ||
| RNA stability regulates differential expression of the metastasis protein, osteopontin, in hepatocellular cancer | Q39972907 | ||
| Thirty-kilodalton Tat-interacting protein suppresses tumor metastasis by inhibition of osteopontin transcription in human hepatocellular carcinoma | Q39974457 | ||
| Heterozygous disruption of the PTEN promotes intestinal neoplasia in APCmin/+ mouse: roles of osteopontin | Q40095123 | ||
| Human macrophages promote the motility and invasiveness of osteopontin-knockdown tumor cells. | Q40124716 | ||
| Cell type-specific post-translational modifications of mouse osteopontin are associated with different adhesive properties | Q40133189 | ||
| Inhibition of osteopontin would suppress angiogenesis in gastric cancer | Q40140301 | ||
| Osteopontin regulation by protein kinase B (Akt) in HepG2 cells. | Q40292566 | ||
| Enhancement of osteopontin expression in HepG2 cells by epidermal growth factor via phosphatidylinositol 3-kinase signaling pathway | Q40600354 | ||
| Isolation and characterization of two sialoproteins present only in bone calcified matrix | Q41978530 | ||
| Osteopontin is a marker for cancer aggressiveness and patient survival | Q42393441 | ||
| Loss of E-cadherin mRNA and gain of osteopontin mRNA are useful markers for detecting early recurrence of HCV-related hepatocellular carcinoma | Q42996730 | ||
| Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas | Q43011700 | ||
| Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria | Q43677417 | ||
| Overexpression of osteopontin in hepatocellular carcinoma | Q43952119 | ||
| Osteopontin as a potential biomarker of proliferation and invasiveness for lung cancer | Q44832836 | ||
| Loss of p16INK4, alone and with overexpression of osteopontin, correlates with survival of patients with spinal metastasis from hepatocellular carcinoma | Q44898833 | ||
| Small integrin binding ligand N-linked glycoprotein gene family expression in different cancers | Q45205095 | ||
| Osteopontin regulates multiple functions contributing to human colon cancer development and progression | Q45243201 | ||
| Aberrant expressions of annexin A10 short isoform, osteopontin and alpha-fetoprotein at chromosome 4q cooperatively contribute to progression and poor prognosis of hepatocellular carcinoma. | Q45309448 | ||
| Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma | Q45409301 | ||
| Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning | Q45728735 | ||
| Immunohistochemical expression of osteopontin in gastric cancer | Q45760104 | ||
| Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection | Q46197500 | ||
| Role of osteopontin and CD44s expression for patients with hepatocellular carcinoma undergoing liver transplantation or resection | Q46245997 | ||
| Post-translational modification and proteolytic processing of urinary osteopontin | Q46855720 | ||
| Expression of osteopontin and CDX2: indications of phenotypes and prognosis in advanced gastric cancer. | Q51825298 | ||
| Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer. | Q51925660 | ||
| DLC1 suppresses distant dissemination of human hepatocellular carcinoma cells in nude mice through reduction of RhoA GTPase activity, actin cytoskeletal disruption and down-regulation of genes involved in metastasis. | Q52587060 | ||
| Osteopontin, a single marker for predicting the prognosis of patients with tumor-node-metastasis stage I hepatocellular carcinoma after surgical resection. | Q53296852 | ||
| Prognostic value of serum osteopontin in hepatocellular carcinoma patients treated with transarterial chemoembolization. | Q53332089 | ||
| An osteopontin fragment is essential for tumor cell invasion in hepatocellular carcinoma. | Q53334223 | ||
| SPP1 polymorphisms associated with HBV clearance and HCC occurrence. | Q53570945 | ||
| Elevated plasma osteopontin levels in patients with hepatocellular carcinoma. | Q53592831 | ||
| Down-regulation of osteopontin suppresses growth and metastasis of hepatocellular carcinoma via induction of apoptosis. | Q54528765 | ||
| Stathmin overexpression cooperates with p53 mutation and osteopontin overexpression, and is associated with tumour progression, early recurrence, and poor prognosis in hepatocellular carcinoma. | Q54598997 | ||
| Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. | Q54766147 | ||
| Expression of osteopontin, a target gene of de-regulated Wnt signaling, predicts survival in colon cancer | Q58913938 | ||
| Co-expression of osteopontin and CD44v9 in gastric cancer | Q74534917 | ||
| The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma | Q79756613 | ||
| Protein expression of osteopontin in tumor tissues is an independent prognostic indicator in gastric cancer | Q79836721 | ||
| Osteopontin promotes integrin activation through outside-in and inside-out mechanisms: OPN-CD44V interaction enhances survival in gastrointestinal cancer cells | Q79856285 | ||
| Positive correlation of osteopontin, cyclooxygenase-2 and vascular endothelial growth factor in gastric cancer | Q80462202 | ||
| Osteopontin silencing by small interfering RNA suppresses in vitro and in vivo CT26 murine colon adenocarcinoma metastasis | Q81300213 | ||
| Prognostic significance of osteopontin expression in human gastric carcinoma | Q81353718 | ||
| Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma | Q81780074 | ||
| The prognostic significance of preoperative plasma levels of osteopontin in patients with TNM stage-I of hepatocellular carcinoma | Q84209884 | ||
| Elevated plasma osteopontin level is predictive of cirrhosis in patients with hepatitis B infection | Q94532504 | ||
| P433 | issue | 30 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | biomarker | Q864574 |
| P304 | page(s) | 3923-3930 | |
| P577 | publication date | 2012-08-01 | |
| P1433 | published in | World Journal of Gastroenterology | Q15708885 |
| P1476 | title | Osteopontin as potential biomarker and therapeutic target in gastric and liver cancers | |
| P478 | volume | 18 |
| Q36425495 | Association between promoter polymorphisms of OPN gene and cancer risk: a meta-analysis |
| Q45737032 | Association of osteopontin expression with the prognosis of glioma patient: a meta-analysis |
| Q38103946 | Circulating markers for prognosis of hepatocellular carcinoma |
| Q60917019 | Determining consistent prognostic biomarkers of overall survival and vascular invasion in hepatocellular carcinoma |
| Q34039967 | Diagnostic and prognostic value of soluble syndecan-1 in pleural malignancies. |
| Q33597930 | Effects of canonical NF-κB signaling pathway on the proliferation and odonto/osteogenic differentiation of human stem cells from apical papilla |
| Q36493158 | Low expression of GNAI3 predicts poor prognosis in patients with HCC. |
| Q26853543 | Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival |
| Q36578825 | Matricellular proteins in drug delivery: Therapeutic targets, active agents, and therapeutic localization |
| Q33867375 | Measuring levels of osteopontin as potential biomarker for hepatocellular carcinoma in Syrian patients |
| Q37415614 | Mechanism of hepatitis C virus (HCV)-induced osteopontin and its role in epithelial to mesenchymal transition of hepatocytes |
| Q27022929 | Mechanisms linking excess adiposity and carcinogenesis promotion |
| Q34775377 | Molecular profiling of stroma identifies osteopontin as an independent predictor of poor prognosis in intrahepatic cholangiocarcinoma |
| Q41504856 | Multiplexed cancer biomarker detection using chip-integrated silicon photonic sensor arrays |
| Q37707767 | NF‑κB inhibition is associated with OPN/MMP‑9 downregulation in cutaneous melanoma |
| Q42200175 | OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC |
| Q38619009 | Osteopontin -- a promising biomarker for cancer therapy |
| Q36408616 | Osteopontin Expression in Patients with Hepatolith |
| Q64232829 | Osteopontin as a biomarker for osteosarcoma therapy and prognosis |
| Q46606704 | Osteopontin as a marker for response to pegylated interferon Alpha-2b treatment in Chronic HCV Saudi patients |
| Q38217758 | Osteopontin as a therapeutic target for cancer |
| Q95725200 | Osteopontin b and c Splice isoforms in Leukemias and Solid Tumors: Angiogenesis Alongside Chemoresistance |
| Q34036685 | Osteopontin knockdown suppresses the growth and angiogenesis of colon cancer cells |
| Q52718495 | Osteopontin regulates HCV replication and assembly via interaction with HCV proteins and lipid droplets and by binding to receptors, αVβ3 and CD44. |
| Q36503987 | Osteopontin splice variants differentially exert clinicopathological features and biological functions in gastric cancer |
| Q37707655 | Osteopontin stimulates apoptosis in adult cardiac myocytes via the involvement of CD44 receptors, mitochondrial death pathway, and endoplasmic reticulum stress. |
| Q53550064 | Osteopontin, E-cadherin, and β-catenin expression as prognostic biomarkers in patients with radically resected gastric cancer. |
| Q26749570 | Osteopontin-A Master Regulator of Epithelial-Mesenchymal Transition |
| Q28248833 | Osteopontin: At the cross-roads of myocyte survival and myocardial function |
| Q37688419 | Prognostic significance of osteopontin expression in gastric cancer: a meta-analysis |
| Q36250701 | Quantification of the concentration gradient of biomarkers between ovarian carcinoma interstitial fluid and blood. |
| Q37707966 | RAN GTPase and Osteopontin in Pancreatic Cancer |
| Q27006644 | Role of osteopontin in systemic lupus erythematosus |
| Q51734190 | SIRT1 overexpression protects non-small cell lung cancer cells against osteopontin-induced epithelial-mesenchymal transition by suppressing NF-κB signaling. |
| Q41020428 | Sildenafil, a Phosphodiesterase Type 5 Inhibitor, Downregulates Osteopontin in Human Peripheral Blood Mononuclear Cells |
| Q38354012 | Targeting osteopontin, the silent partner of Na+/H+ exchanger isoform 1 in cardiac remodeling |
| Q87851600 | The prognostic value of osteopontin expression in non-small cell lung cancer: a meta-analysis |
| Q40973252 | The role of osteopontin expression in melanoma progression |
| Q50544691 | microRNAs and Endometrial Pathophysiology. |
Search more.